Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
about
Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patientsGenomic diversity of colorectal cancer: Changing landscape and emerging targetsGastric biomarkers: a global reviewHER2 testing in gastric cancer: An updateState of the art management of metastatic gastroesophageal cancerHER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the StomachSerum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-AnalysisThe genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondFrom molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancerCopy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants.The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing.Clinical impact of tumour biology in the management of gastroesophageal cancerHER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.Tumour heterogeneity in the clinic.The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancerThe advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.Gastric cancer: current status of diagnosis and treatmentAssociation between HSP90 and Her2 in gastric and gastroesophageal carcinomas.Recent advances in the HER2 targeted therapy of gastric cancerBrain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2).A HER2 selective theranostic agent for surgical resection guidance and photodynamic therapy.Targeted therapy in gastroesophageal cancers: past, present and future.Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies.The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literatureDiscordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancerSerum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.Subtotal gastrectomy with conventional D2 lymphadenectomy for carcinoma of the distal gastric portion: A retrospective cohort study on clinical outcomesLauren classification and individualized chemotherapy in gastric cancer.Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population.Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapiesPRL3-zumab, a first-in-class humanized antibody for cancer therapy.HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients.HER2-positive gastric cancer.Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines.Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device.
P2860
Q21261244-90A4037C-E817-4986-8ADC-FA3ACC1C753AQ26739052-1778F1C4-9C99-41FE-A4AE-7E39DC0B5493Q26741859-0B4304CE-5315-4AE6-97D1-B61FA13F944EQ26746253-50C48CEB-1A80-4002-92C5-1F3481880132Q26779217-AF3D8B55-FE97-454F-A849-E11EF01F4930Q26780318-DF4F4B5D-C73E-413A-81F4-7FFC43E0B5BDQ26796280-CBFCCA12-891A-4911-95BC-2D443A4207F6Q28078788-51F7D817-60F0-454B-B9CB-74F4BD0B8E6CQ28082921-93C4C671-8BB0-4967-A17F-D9EA5CD0C14AQ31105539-699D365E-283C-46B7-8412-B96B6A07872EQ33764191-78BD4BEE-EF33-4BE0-A31B-2AC06161C648Q33922534-052A96F1-2DE6-44AE-B608-A65477DC245BQ34324291-EEEA4A0C-DD0E-4F1B-8C57-A29A6D34DCDBQ34372080-CF6AC66E-E326-4E08-9BB1-FBD2AFB39C95Q34478504-6A585F82-8E50-4F0D-BCB1-EB6398AEEDEBQ34648886-1E007788-0300-4533-8126-642567FC8F0EQ34657361-62E684E1-56C3-46D6-AC03-AAB0767B16DBQ34852929-EDEFE2CD-E571-4EF1-B821-B5C5511D3113Q34967104-3D3A848D-ECCB-4DA5-9889-5257C0E7FBE2Q36027093-C22C1641-BD0C-49BE-9E03-727FD4487A96Q36097775-18C7BE7D-1B6E-4CEF-B7BF-2E45FB120453Q36294579-7E8DC99A-DC93-42F7-99FA-467CA20F1D3AQ36303653-61A72C7F-6192-4D38-9AB4-7659D99BF05EQ36309934-944AAD3C-025C-4CFE-82E5-B720D53DD89EQ36317603-39291E94-F768-4F80-BD53-EDD739CD665BQ36666667-6EED1D20-EF59-4B7F-AEDF-3F8EE612CA22Q36778082-139466A0-AF9B-4C2A-8BF8-CBDCF672DF91Q36782629-3DA4222D-5D8E-4943-9EE7-EA59110D66F6Q36823762-F6D548CE-A3FA-4C51-8771-87316048B387Q36824887-B7687024-FBD6-4BA8-985D-B197C4C6F3DBQ36897947-6DA63E14-61D9-484D-B7A5-AE5946633054Q36950483-0D74BE38-2A79-4025-B41F-E93D9AAA2E69Q37013285-57525C43-6185-44DB-8D96-C2C02F9293F3Q37241496-041D2A5B-EA7D-4F64-A778-C470C16DD048Q37277211-74F9A7E3-5FAF-4777-AA55-5EBAC60E0F77Q37308782-BE4EBF24-F48D-45E1-8B20-C688119D1C5BQ37392861-E55C1496-9487-4BCA-8D20-3C733C8B35EBQ37468290-458B0C5F-14D9-48D3-939F-2170A7F9FE8BQ37559437-2B2D9D31-4263-4100-A427-3FD004EDE559Q37577818-EF2D2910-7FDF-40DA-B6F0-D4D93A01816D
P2860
Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Prognosis of metastatic gastri ...... tional collaborative analysis.
@en
Prognosis of metastatic gastri ...... tional collaborative analysis.
@nl
type
label
Prognosis of metastatic gastri ...... tional collaborative analysis.
@en
Prognosis of metastatic gastri ...... tional collaborative analysis.
@nl
prefLabel
Prognosis of metastatic gastri ...... tional collaborative analysis.
@en
Prognosis of metastatic gastri ...... tional collaborative analysis.
@nl
P2093
P2860
P356
P1433
P1476
Prognosis of metastatic gastri ...... tional collaborative analysis.
@en
P2093
D P Kelsen
E Robinson
H-M Altmannsberger
K Steinmetz
P2860
P304
P356
10.1093/ANNONC/MDS104
P577
2012-06-11T00:00:00Z